Previous studies have shown that SCU can overcome resistance to cisplatin-induced apoptosis and autophagy in NSCLC by activating the ERK/p53 and c-met/Akt signaling pathways (Sun et al., 2018). Here, TP53 is linked to non-small cell lung carcinoma.